Developer docs
API playgroundTry for free, no card

Search company profiles

7HC

Full company profile

uuid0021pv1

Namestring
7HC
Legal namestring
7HC S.r.l.
Websiteurl
7hc.tech
Company typeenum
Private
Founded yearint
2021
Descriptiontext

7HC S.r.l. (7 Health Computing) is an Italian computational biology company founded in 2021 and headquartered in Rome. The company has built a cloud-based software platform for in silico prediction of pharmacological efficacy, allowing pharmaceutical and red-biotech users to estimate drug-receptor affinity, pharmacokinetics, and small-molecule physiology (water solubility, logP, logD, Kd, IC50, blood-brain barrier penetration, drug likeness, toxicity) directly from SMILES molecular strings and protein amino acid sequences. The platform runs on Amazon EC2 and S3, integrates with the Protein Data Bank, and uses GROMACS for pharmaco-receptor interaction kinetics calculations; it automatically selects the best ML model per query type. The platform is delivered as a web-based SaaS solution targeting pharmaceutical firms, red-biotech companies, clinical practitioners (via an explainable-ML Cardiovascular Risk Predictor), and precision nutrition/agriculture users through specialized modules.

The company's product portfolio includes the core 7HC Computational Platform, a Drug Property Prediction Module, a Clinical Decision Support module, the COVID-19 Piacenza Score (published 2021 in JMIR), a Precision Nutrition and Agriculture module, and emerging AI-based Virtual Cell Models / digital twins for neurodegenerative disorders. Business operations are dominated by EU-funded research consortium participation rather than disclosed commercial SaaS sales: 7HC is a partner in at least nine EU programmes (Horizon MSCA-ITN/SE, PNRR Partenariato Esteso FAIR/RETURN, Eurostars), including the €2.3M NEUROSPARK project (announced February 2026) targeting Spinocerebellar Ataxia Type 3 with InVirtuoLabs, INSYBIO, and oloBion. The leadership team comprises a PhD CEO with 20+ years in biomedical engineering and a CTO with prior database engineering experience at Expedia, Booking.com, LastMinute, and Telefonica Group; the organization has 1–10 employees and no disclosed external venture funding.

Short descriptiontext

7HC is an Italian cloud-based software company that provides in silico drug discovery and pharmacology prediction tools — drug-target affinity, ADMET, and patient health trajectory — to pharmaceutical firms, red-biotech companies, clinical practitioners, and precision nutrition users, primarily through EU-funded research consortium participation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersRome, Italy
HQ citystring
Rome
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
computational drug discovery, in silico pharmacology, cloud drug design, biotech software platform, molecular modeling services
Industry1 code
PRIMARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Computational Drug Discovery Software
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1SaaS Platform Access
TypeSubscription Recurring
Description

7HC provides its computational platform as a cloud-based service on demand. The platform manages IT resources for data storage, processing and transmission according to user requests. Pharmaceutical companies and biotech firms access the service through a web interface without requiring expensive hardware resources.

7hc.tech
2Research Collaboration and Grants
TypeProfessional Services
Description

7HC participates in EU-funded research projects (Horizon Europe, MSCA, PNRR) as a consortium partner. These collaborative research projects contribute to technology development and operational funding.

7hc.tech
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Infrastructure, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

7HC provides a cloud-based computational platform for in silico prediction of pharmacological efficacy, targeting pharmaceutical industries and red-biotech companies. The platform processes molecular inputs (SMILES strings and protein sequences) through machine learning algorithms to estimate drug-receptor affinity, pharmacokinetics, water solubility, logP/logD, Kd/IC50, blood-brain barrier penetration, and toxicity. Delivered as a web-based SaaS, it supports drug design and optimization, clinical decision support (cardiovascular risk), and precision nutrition applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Reduces the number of experiments required in the first phase of drug development
+2 more records
Product overview1 text field

7HC is a unified computational platform combining Internet of Things and Cloud Computing technologies for healthcare applications. The core 7HC Computational Platform serves as an integrated software platform for in silico drug discovery, complemented by specialized modules including the Cardiovascular Risk Predictor for clinical decision support, the Drug Property Prediction Module for pharmaceutical research, and the Precision Nutrition Platform for agriculture and nutrition applications. The platform processes molecular inputs (SMILES strings and protein sequences) through machine learning algorithms to predict drug efficacy, pharmacokinetics, and patient health trajectories, accessible via web-based interface.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-11
Description

InVirtuoLabs, a biotech startup, leads the €2.3 million Eurostars-funded NEUROSPARK project. 7HC participates as a partner along with INSYBIO (Greece) and oloBion (Spain). The 36-month project aims to identify and validate 3-5 lead small molecules for Spinocerebellar Ataxia Type 3 (SCA3) using AI-based Virtual Cell Models as digital twins of diseased cells.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Greek biotech company partner in the NEUROSPARK Eurostars grant project for SCA3 drug discovery.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Spanish biotech company partner in the NEUROSPARK Eurostars grant project for SCA3 drug discovery.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Cellex s.r.l coordinates the 3D-creator project for developing an automated platform for bioengineered tissue culture (bone and esophageal tissues). 7HC participates along with Fondazione Edoardo Amaldi and CNR Institute of Translational Pharmacology.

5Fondazione Edoardo Amaldi (FEA)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

The E. Amaldi Foundation is a partner in the 3D-creator project for automated bioengineered tissue culture platform development.

7hc.tech
6CNR Institute of Translational Pharmacology (IFT)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

The Institute of Translational Pharmacology of the National Research Council (CNR) is a partner in the 3D-creator project for automated bioengineered tissue culture platform development.

7hc.tech
7PARENT Consortium (Horizon MSCA-ITN)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

PARENT is a Horizon-MSCA-ITN-2020 project (Grant Agreement N° 956394) focused on early diagnosis of newborn motor/cognitive impairments. 7HC participates in this multidisciplinary and inter-sectorial network of European research groups, industry partners, pediatric hospitals and associations, training 15 Early Stage Researchers.

7hc.tech
8OSTEONET Consortium (Horizon MSCA-SE)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

OSTEONET is a Horizon-MSCA-SE-2021 project (Grant Agreement N° 101086329) developing in vitro 3D cell models of healthy and osteopathological ageing bone tissue for implantation and drug testing.

7hc.tech
Strategic tierMajorTypeStrategic or Co-development Partner
Description

FAIR is a PNNR Partenariato Esteso (Extended Partnership) focused on Human-Centered AI. The TECHNET project, in which 7HC participates, aligns with FAIR objectives (Spoke 1, themes TP3 and TP6) for automated emotion analysis during Narrative Exposure Therapy.

10RETURN Consortium (PNRR)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

RETURN is a PNRR Partenariato Esteso focused on Multi-Risk Science for resilient communities under a changing climate. 7HC participates in Spoke 5 (Urban Settlements) through the URBAN SHIELD project for monitoring urban transformations and environmental risk analysis.

7hc.tech
11SOSVITI Consortium (Horizon MSCA-SE)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

SOSVITI is a Horizon-MSCA-SE-2023 project (Grant Agreement N° 101182765) developing an advanced framework for sustainable soil management in viticulture using AI, remote sensing, and decision-support tools.

7hc.tech
12Galatea Consortium (Horizon MSCA-SE)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Galatea is a Horizon-MSCA-SE-2023 project (Grant Agreement N° 101183057) developing a digital twin of human milk for personalized infant nutrition, particularly for prematurely born infants.

7hc.tech
13SMARTOLIVE Consortium (Horizon MSCA-SE)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

SMARTOLIVE is a Horizon-MSCA-SE-2024 project (Grant Agreement N° 101236434) developing a Decision Support System for modern olive farming, using IoT and AI for supply chain management.

7hc.tech
14WATERDEAL Consortium (Horizon MSCA-SE)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

WATERDEAL is a Horizon-MSCA-SE-2025 project (Grant Agreement N° 101299840) addressing water scarcity through IoT, AI-driven analytics, and cloud-edge computing for smart Water Supply Systems.

7hc.tech
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Owkin applies AI to biomedical research and clinical outcomes, with a focus on explainable ML for clinical decision support. Overlaps with 7HC's Cardiovascular Risk Predictor and explainable-ML clinical decision support offering.

TypeDirect peer
Description

Exscientia is an AI-driven pharmatech combining ML with automated chemistry to design and develop novel small molecules. Comparable to 7HC as both companies pursue AI-first drug design with pharma partnerships and proprietary pipelines.

TypeBroad incumbent
Description

Recursion combines high-throughput biology with AI/ML for drug discovery, with a deep pipeline in rare diseases and phenomics. It is a broad incumbent operating at scale in AI-driven pharma R&D — the same category where 7HC competes.

4Iambic Therapeutics
TypeEmerging player
Description

Iambic Therapeutics (formerly Entasis Therapeutics's AI arm) uses AI/ML for small-molecule design and prediction of clinical PK/PD outcomes. Comparable emerging player with similar focus on AI-native molecular property prediction and therapy optimisation.

TypeDirect peer
Description

XtalPi combines AI, quantum physics, and cloud computing to predict small-molecule properties and crystal forms for pharma R&D. Direct overlap with 7HC's cloud-based molecular property and binding prediction workflow.

TypeBroad incumbent
Description

Schrödinger operates a physics-informed computational platform for molecular simulation and drug discovery (LiveDesign). It is a broad incumbent covering the same AI/ML-driven molecular property and binding prediction use cases that 7HC's core platform addresses, but at much larger scale and with an established pharma customer base.

TypeDirect peer
Description

Atomwise provides AI-driven small-molecule discovery using deep learning on protein-ligand binding (AtomNet). It directly competes with 7HC on automated molecular property prediction and virtual screening for pharma and biotech customers.

TypeDirect peer
Description

BenevolentAI applies AI/ML to drug discovery and clinical development, combining biomedical knowledge graphs with ML to identify targets and predict efficacy. Overlaps with 7HC's drug-target affinity prediction and patient health trajectory modelling.

TypeDirect peer
Description

Insilico Medicine is an AI-driven drug discovery company using generative chemistry, target identification, and clinical prediction. It is a direct peer to 7HC's computational pharma platform, especially around ML-based drug property and PK/PD prediction.

TypeDirect peer
Description

InVirtuoLabs is a biotech that builds AI-based Virtual Cell Models / digital twins for lead molecule identification and validation. It is a consortium partner of 7HC in NEUROSPARK, but also a direct peer because both companies apply AI virtual cell/digital-twin methodologies to small-molecule discovery in rare disease.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI capability12 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

7HC

Computational Drug Discovery Software7hc.tech

7HC is an Italian cloud-based software company that provides in silico drug discovery and pharmacology prediction tools — drug-target affinity, ADMET, and patient health trajectory — to pharmaceutical firms, red-biotech companies, clinical practitioners, and precision nutrition users, primarily through EU-funded research consortium participation.

What 7HC does

7HC S.r.l. (7 Health Computing) is an Italian computational biology company founded in 2021 and headquartered in Rome. The company has built a cloud-based software platform for in silico prediction of pharmacological efficacy, allowing pharmaceutical and red-biotech users to estimate drug-receptor affinity, pharmacokinetics, and small-molecule physiology (water solubility, logP, logD, Kd, IC50, blood-brain barrier penetration, drug likeness, toxicity) directly from SMILES molecular strings and protein amino acid sequences. The platform runs on Amazon EC2 and S3, integrates with the Protein Data Bank, and uses GROMACS for pharmaco-receptor interaction kinetics calculations; it automatically selects the best ML model per query type. The platform is delivered as a web-based SaaS solution targeting pharmaceutical firms, red-biotech companies, clinical practitioners (via an explainable-ML Cardiovascular Risk Predictor), and precision nutrition/agriculture users through specialized modules.

The company's product portfolio includes the core 7HC Computational Platform, a Drug Property Prediction Module, a Clinical Decision Support module, the COVID-19 Piacenza Score (published 2021 in JMIR), a Precision Nutrition and Agriculture module, and emerging AI-based Virtual Cell Models / digital twins for neurodegenerative disorders. Business operations are dominated by EU-funded research consortium participation rather than disclosed commercial SaaS sales: 7HC is a partner in at least nine EU programmes (Horizon MSCA-ITN/SE, PNRR Partenariato Esteso FAIR/RETURN, Eurostars), including the €2.3M NEUROSPARK project (announced February 2026) targeting Spinocerebellar Ataxia Type 3 with InVirtuoLabs, INSYBIO, and oloBion. The leadership team comprises a PhD CEO with 20+ years in biomedical engineering and a CTO with prior database engineering experience at Expedia, Booking.com, LastMinute, and Telefonica Group; the organization has 1–10 employees and no disclosed external venture funding.

7HC firmographics

Firmographics
Name
7HC
Legal name
7HC S.r.l.
Website
https://7hc.tech
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
7HC is an Italian cloud-based software company that provides in silico drug discovery and pharmacology prediction tools — drug-target affinity, ADMET, and patient health trajectory — to pharmaceutical firms, red-biotech companies, clinical practitioners, and precision nutrition users, primarily through EU-funded research consortium participation.
Ownership category
akta.pro rank

7HC industry classification

Industry
Product category
Computational Drug Discovery Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Computational drug discovery
  • In silico pharmacology
  • Cloud drug design
  • Biotech software platform
  • Molecular modeling services

Where 7HC is headquartered

Location

Headquarters

HQ city
Rome
HQ country
Italy
HQ region
Europe

Offices1 record

Markets served

7HC business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Infrastructure, Operations

Revenue model

  1. SaaS Platform Access: 7HC provides its computational platform as a cloud-based service on demand. The platform manages IT resources for data storage, processing and transmission according to user requests. Pharmaceutical companies and biotech firms access the service through a web interface without requiring expensive hardware resources.
  2. Research Collaboration and Grants: 7HC participates in EU-funded research projects (Horizon Europe, MSCA, PNRR) as a consortium partner. These collaborative research projects contribute to technology development and operational funding.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

7HC product offering

Product offering

Core offering

7HC provides a cloud-based computational platform for in silico prediction of pharmacological efficacy, targeting pharmaceutical industries and red-biotech companies. The platform processes molecular inputs (SMILES strings and protein sequences) through machine learning algorithms to estimate drug-receptor affinity, pharmacokinetics, water solubility, logP/logD, Kd/IC50, blood-brain barrier penetration, and toxicity. Delivered as a web-based SaaS, it supports drug design and optimization, clinical decision support (cardiovascular risk), and precision nutrition applications.

Product overview

7HC is a unified computational platform combining Internet of Things and Cloud Computing technologies for healthcare applications. The core 7HC Computational Platform serves as an integrated software platform for in silico drug discovery, complemented by specialized modules including the Cardiovascular Risk Predictor for clinical decision support, the Drug Property Prediction Module for pharmaceutical research, and the Precision Nutrition Platform for agriculture and nutrition applications. The platform processes molecular inputs (SMILES strings and protein sequences) through machine learning algorithms to predict drug efficacy, pharmacokinetics, and patient health trajectories, accessible via web-based interface.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Reduces the number of experiments required in the first phase of drug development
  • +2 more outcomes

Companies that use 7HC

Customer profile

Segments4 records

Ideal customer profiles3 records

7HC technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability12 records

Feature5 records

7HC partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered core, major and minor.

  • InVirtuoLabscoreStrategic or Co-development Partner · 11 February 2026InVirtuoLabs, a biotech startup, leads the €2.3 million Eurostars-funded NEUROSPARK project. 7HC participates as a partner along with INSYBIO (Greece) and oloBion (Spain). The 36-month project aims to identify and validate 3-5 lead small molecules for Spinocerebellar Ataxia Type 3 (SCA3) using AI-based Virtual Cell Models as digital twins of diseased cells.
  • INSYBIOcoreStrategic or Co-development PartnerGreek biotech company partner in the NEUROSPARK Eurostars grant project for SCA3 drug discovery.
  • oloBioncoreStrategic or Co-development PartnerSpanish biotech company partner in the NEUROSPARK Eurostars grant project for SCA3 drug discovery.
  • Cellex s.r.lmajorStrategic or Co-development PartnerCellex s.r.l coordinates the 3D-creator project for developing an automated platform for bioengineered tissue culture (bone and esophageal tissues). 7HC participates along with Fondazione Edoardo Amaldi and CNR Institute of Translational Pharmacology.
  • Fondazione Edoardo Amaldi (FEA)majorStrategic or Co-development PartnerThe E. Amaldi Foundation is a partner in the 3D-creator project for automated bioengineered tissue culture platform development.
  • CNR Institute of Translational Pharmacology (IFT)majorStrategic or Co-development PartnerThe Institute of Translational Pharmacology of the National Research Council (CNR) is a partner in the 3D-creator project for automated bioengineered tissue culture platform development.
  • PARENT Consortium (Horizon MSCA-ITN)majorStrategic or Co-development PartnerPARENT is a Horizon-MSCA-ITN-2020 project (Grant Agreement N° 956394) focused on early diagnosis of newborn motor/cognitive impairments. 7HC participates in this multidisciplinary and inter-sectorial network of European research groups, industry partners, pediatric hospitals and associations, training 15 Early Stage Researchers.
  • OSTEONET Consortium (Horizon MSCA-SE)majorStrategic or Co-development PartnerOSTEONET is a Horizon-MSCA-SE-2021 project (Grant Agreement N° 101086329) developing in vitro 3D cell models of healthy and osteopathological ageing bone tissue for implantation and drug testing.
  • FAIR Program (Future Artificial Intelligence Research)majorStrategic or Co-development PartnerFAIR is a PNNR Partenariato Esteso (Extended Partnership) focused on Human-Centered AI. The TECHNET project, in which 7HC participates, aligns with FAIR objectives (Spoke 1, themes TP3 and TP6) for automated emotion analysis during Narrative Exposure Therapy.
  • RETURN Consortium (PNRR)majorStrategic or Co-development PartnerRETURN is a PNRR Partenariato Esteso focused on Multi-Risk Science for resilient communities under a changing climate. 7HC participates in Spoke 5 (Urban Settlements) through the URBAN SHIELD project for monitoring urban transformations and environmental risk analysis.
  • SOSVITI Consortium (Horizon MSCA-SE)minorStrategic or Co-development PartnerSOSVITI is a Horizon-MSCA-SE-2023 project (Grant Agreement N° 101182765) developing an advanced framework for sustainable soil management in viticulture using AI, remote sensing, and decision-support tools.
  • Galatea Consortium (Horizon MSCA-SE)minorStrategic or Co-development PartnerGalatea is a Horizon-MSCA-SE-2023 project (Grant Agreement N° 101183057) developing a digital twin of human milk for personalized infant nutrition, particularly for prematurely born infants.
  • SMARTOLIVE Consortium (Horizon MSCA-SE)minorStrategic or Co-development PartnerSMARTOLIVE is a Horizon-MSCA-SE-2024 project (Grant Agreement N° 101236434) developing a Decision Support System for modern olive farming, using IoT and AI for supply chain management.
  • WATERDEAL Consortium (Horizon MSCA-SE)minorStrategic or Co-development PartnerWATERDEAL is a Horizon-MSCA-SE-2025 project (Grant Agreement N° 101299840) addressing water scarcity through IoT, AI-driven analytics, and cloud-edge computing for smart Water Supply Systems.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

7HC competitors and assessment

Company assessment

Emerging players

  • Owkin: Owkin applies AI to biomedical research and clinical outcomes, with a focus on explainable ML for clinical decision support. Overlaps with 7HC's Cardiovascular Risk Predictor and explainable-ML clinical decision support offering.
  • Iambic Therapeutics: Iambic Therapeutics (formerly Entasis Therapeutics's AI arm) uses AI/ML for small-molecule design and prediction of clinical PK/PD outcomes. Comparable emerging player with similar focus on AI-native molecular property prediction and therapy optimisation.

Direct peers

  • Exscientia: Exscientia is an AI-driven pharmatech combining ML with automated chemistry to design and develop novel small molecules. Comparable to 7HC as both companies pursue AI-first drug design with pharma partnerships and proprietary pipelines.
  • XtalPi: XtalPi combines AI, quantum physics, and cloud computing to predict small-molecule properties and crystal forms for pharma R&D. Direct overlap with 7HC's cloud-based molecular property and binding prediction workflow.
  • Atomwise: Atomwise provides AI-driven small-molecule discovery using deep learning on protein-ligand binding (AtomNet). It directly competes with 7HC on automated molecular property prediction and virtual screening for pharma and biotech customers.
  • BenevolentAI: BenevolentAI applies AI/ML to drug discovery and clinical development, combining biomedical knowledge graphs with ML to identify targets and predict efficacy. Overlaps with 7HC's drug-target affinity prediction and patient health trajectory modelling.
  • Insilico Medicine: Insilico Medicine is an AI-driven drug discovery company using generative chemistry, target identification, and clinical prediction. It is a direct peer to 7HC's computational pharma platform, especially around ML-based drug property and PK/PD prediction.
  • InVirtuoLabs: InVirtuoLabs is a biotech that builds AI-based Virtual Cell Models / digital twins for lead molecule identification and validation. It is a consortium partner of 7HC in NEUROSPARK, but also a direct peer because both companies apply AI virtual cell/digital-twin methodologies to small-molecule discovery in rare disease.

Broad incumbents

  • Recursion Pharmaceuticals: Recursion combines high-throughput biology with AI/ML for drug discovery, with a deep pipeline in rare diseases and phenomics. It is a broad incumbent operating at scale in AI-driven pharma R&D — the same category where 7HC competes.
  • Schrödinger, Inc. Schrödinger operates a physics-informed computational platform for molecular simulation and drug discovery (LiveDesign). It is a broad incumbent covering the same AI/ML-driven molecular property and binding prediction use cases that 7HC's core platform addresses, but at much larger scale and with an established pharma customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

7HC social profiles

Digital presence

7HC financial estimates

Financial estimate

Revenue estimate

Valuation estimate

7HC leadership team

Management profile

Number of profiles

Profiles3 records

7HC funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

7HC M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 7HC

What does 7HC do?

7HC provides a cloud-based computational platform for in silico prediction of pharmacological efficacy, targeting pharmaceutical industries and red-biotech companies. The platform processes molecular inputs (SMILES strings and protein sequences) through machine learning algorithms to estimate drug-receptor affinity, pharmacokinetics, water solubility, logP/logD, Kd/IC50, blood-brain barrier penetration, and toxicity. Delivered as a web-based SaaS, it supports drug design and optimization, clinical decision support (cardiovascular risk), and precision nutrition applications.

Is 7HC a public or private company?

7HC is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was 7HC founded?

7HC was founded in 2021. It employs 1 to 10 people.

Where is 7HC based?

7HC is headquartered in Rome, Italy, in the Europe region.

How does 7HC make money?

Two revenue lines are on record. SaaS Platform Access are the primary driver. The others are research Collaboration and Grants.

Who are 7HC's main competitors?

Emerging players on record are Owkin and Iambic Therapeutics. Direct peers are Exscientia, XtalPi, Atomwise, BenevolentAI, Insilico Medicine and InVirtuoLabs. Broad incumbents are Recursion Pharmaceuticals and Schrödinger, Inc..

Does 7HC have an API?

No public API is recorded for 7HC.

What industry is 7HC in?

7HC's product category is Computational Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAE, Cheminformatics & Molecular Modeling / CADD. Its NAICS code is 541714 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales